Grzegorz Nowakowski, MD
Hematology · Rochester, MNNPI 1629040076
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $189,337 of the $234,999 with a category attached, or 80.6%. It is spread thinly across 21 manufacturers, the largest accounting for just 12.2%. 2025 is the largest year on record at $66,151, 9.4 times the $7,043 reported in 2019. Among hematology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 174 payments — averaging $1350.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$29K
- E.r. Squibb & Sons, L.L.C.$27K
- Incyte Corporation$26K
- Bristol Myers Squibb$26K
- Gilead$22K
- F. Hoffmann-la Roche AG$20K
- plus $85K from 15 others
Across 244 payments — averaging $36,245 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$3.5M
- AstraZeneca$1.3M
- Seagen Inc.$1.1M
- Morphosys AG$994K
- Genmab U.S., Inc.$774K
- Incyte Corporation$337K
- plus $895K from 9 others
What the payments were for
- Consulting fees$189,33781%
- Speaking & faculty fees$17,4867%
- Travel & lodging$24,78511%
- Food & beverage$3,3921%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 26 | $28,698 |
| E.r. Squibb & Sons, L.L.C. | 24 | $27,260 |
| Incyte Corporation | 10 | $25,838 |
| Bristol Myers Squibb | 49 | $25,559 |
| Gilead | 15 | $22,394 |
| F. Hoffmann-la Roche AG | 7 | $19,854 |
| Urogen Pharma, Inc. | 6 | $14,229 |
| Astrazeneca UK Limited | 3 | $13,295 |
| Acrotech Biopharma Inc. | 1 | $11,900 |
| Genmab U.S., Inc. | 4 | $7,920 |
| Morphosys, US Inc. | 3 | $6,943 |
| AbbVie | 8 | $6,632 |
| Regeneron | 4 | $5,562 |
| Daiichi Sankyo Inc. | 4 | $4,863 |
| ADC Therapeutics America, Inc. | 3 | $3,689 |
| Karyopharm Therapeutics Inc. | 1 | $2,295 |
| Genentech USA, Inc. | 1 | $2,280 |
| Seagen Inc. | 2 | $1,987 |
| Genentech, Inc. | 1 | $1,980 |
| Amgen | 1 | $1,372 |
| Morphosys AG | 1 | $450 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$234,999 in reported general payments places this provider in the 95th percentile of 111 hematology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 20 | $396,177 |
| Acyclovir | 13 | $143 |
| Prochlorperazine Maleate | 11 | $131 |
Paid to pharmacies, not to this prescriber.
Other hematology in Rochester
- Shaji KumarRochester$452K
- Yi LinRochester$365K
- David DingliRochester$299K
- Morie GertzRochester$261K
- Sameer ParikhRochester$151K
- Lindsey RoekerRochester$106K
- Mark LitzowRochester$99K
- Angela DispenzieriRochester$87K
- Prashant KapoorRochester$71K
- Thomas WitzigRochester$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.